Citigroup Inc Talaris Therapeutics, Inc. Transaction History

Citigroup Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$1.78 - $3.2 $1.51 Million - $2.72 Million	-849,873 Reduced 99.99%	88 $0
Q1 2023 May 11, 2023	BUY	$1.09 - $2.09 $926,211 - $1.78 Million	849,735 Added 375988.94%	849,961 $1.6 Million
Q4 2022 Feb 09, 2023	SELL	$0.94 - $1.64 $639 - $1,115	-680 Reduced 75.06%	226 $0
Q3 2022 Nov 10, 2022	SELL	$2.3 - $5.03 $3,217 - $7,036	-1,399 Reduced 60.69%	906 $2,000
Q2 2022 Aug 10, 2022	BUY	$4.51 - $9.85 $2,751 - $6,008	610 Added 35.99%	2,305 $10,000
Q1 2022 May 12, 2022	SELL	$6.89 - $16.56 $37,247 - $89,523	-5,406 Reduced 76.13%	1,695 $17,000
Q4 2021 Feb 10, 2022	BUY	$12.18 - $17.0 $70,924 - $98,991	5,823 Added 455.63%	7,101 $109,000
Q3 2021 Nov 10, 2021	BUY	$11.61 - $15.99 $14,837 - $20,435	1,278 New	1,278 $17,000

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.